SCHEMBL6286907

SCHEMBL6286907

CC(C)(C)OC(=O)[C@H](Cc1ccc(O)cc1)Nc1nc2ccccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
LY96 Q9Y6Y9 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
ALDH1A1 P00352 5/20 0.44
CYP1A2 P05177 2/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1595124 0.89 ELANE (0.57) ELANENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL468299 0.86 PTPRB (0.51) CYP2C19CYP3A4CYP2C8CYP2C9NPR3
SCHEMBL468297 0.86 PTPRB (0.51) CYP2C19CYP3A4CYP2C8CYP2C9NPR3
SCHEMBL27750801 0.86 HDAC3 (0.41) NPC1RAB9ASMN1; SMN2HDAC3HDAC4
SCHEMBL4831646 0.86 ITGB1 (0.48) NPC1RAB9ASMN1; SMN2HDAC3HDAC4
SCHEMBL3144746 0.83 CSNK1D (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL6284775 0.82 MAPK1 (0.46) NPC1RAB9ASMN1; SMN2HDAC3HDAC4
SCHEMBL9531007 0.79 NPC1 (0.59) ELANENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL9009399 0.79 NPC1 (0.59) ELANENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL7693379 0.78 LY96 (0.48) ELANELY96MAPTCYP2C19ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6838453-B2 Antagonist derivatives of the vitronectin receptor AVENTIS PHARMA S.A. (FR) 2005-01-04 US disclosed
US-20040225111-A1 ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR AVENTIS PHARMA S.A. (FR) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225111-A1 ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR ADGRF1, BDKRB1, ADGRE5 ELANE 805/4885NPC1 1519/4885RAB9A 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.